Here is what the page “Lung Cancer Survivor on Targeted Therapy: 15 Years Alive, But Quality of Life Overlooked” contains. A lung cancer patient who has survived 15 years on a targeted drug is speaking out about a critical gap in cancer research: the focus on survival statistics over quality of life for survivors. Her story highlights the double-edged nature of precision medicine, which can keep patients alive long-term but often comes with side effects and challenges that are seldom discussed. While she thrived, many of her friends on similar treatments did not, underscoring the unpredictable nature of cancer therapies.
The patient argues that researchers and clinicians must pay more attention to how survivors actually live, not just how long. Her perspective calls for a shift toward patient-centered outcomes in oncology. As targeted therapies become more common, her message is a reminder that survival is only part of the story. The full version stays on the original page, which this listing opens directly.